Abraham Shaked

Title: Abraham Shaked: Innovator in Transplant Diagnostics

Introduction

Abraham Shaked is a prominent inventor based in Wynnewood, PA (US). He has made significant contributions to the field of transplant medicine, particularly in the diagnosis and treatment of transplant rejection. With a total of 3 patents, his work has the potential to greatly improve patient outcomes in transplant procedures.

Latest Patents

One of Shaked's latest patents focuses on the use of micro-ribonucleic acid (miRNA) to diagnose transplant rejection and tolerance of immunosuppression therapy. This invention relates to the discovery that certain miRNAs can serve as a diagnostic signature to predict transplant outcomes in recipients. The methods described in this patent include diagnosing acute cellular rejection (ACR) and assessing the likelihood of successful immunosuppression therapy dosage adjustments.

Another significant patent involves methods to detect, treat, and prevent acute cellular rejection in kidney allografts. This patent outlines a 3-gene molecular signature analysis of specific RNAs in urinary sample cells, which can be used for the diagnosis and prognosis of acute cellular rejection in kidney transplants.

Career Highlights

Abraham Shaked has worked with esteemed institutions such as the University of Pennsylvania and Cornell University. His research and innovations have been instrumental in advancing the understanding of transplant rejection mechanisms and improving diagnostic techniques.

Collaborations

Shaked has collaborated with notable colleagues, including Manikkam Suthanthiran and Ruchuang Ding. Their combined expertise has contributed to the development of groundbreaking methods in transplant diagnostics.

Conclusion

Abraham Shaked's innovative work in the field of transplant medicine highlights the importance of research in improving patient care. His patents reflect a commitment to enhancing diagnostic capabilities and treatment options for transplant recipients.